However, in addition, some sporadic tumours share a phenotype similar to familial-BRCA cancers due to epigenetic mechanisms of gene inactivation (termed ‘BRCAness’ phenotype) and it is predicted that these patients could potentially derive clinical benefit from PARP inhibition (Turner et al, 2004). Here, PARP1 is linked to cancer.